On Oct 30, major Wall Street analysts update their ratings for $AtriCure (ATRC.US)$, with price targets ranging from $36 to $60.
UBS analyst Danielle Antalffy maintains with a buy rating, and adjusts the target price from $35 to $40.
Oppenheimer analyst Suraj Kalia maintains with a buy rating, and adjusts the target price from $32 to $36.
Needham analyst Michael Matson maintains with a buy rating, and adjusts the target price from $34 to $40.
BTIG analyst Marie Thibault maintains with a buy rating, and maintains the target price at $53.
CCORF analyst William Plovanic maintains with a buy rating, and adjusts the target price from $49 to $53.
Furthermore, according to the comprehensive report, the opinions of $AtriCure (ATRC.US)$'s main analysts recently are as follows:
AtriCure delivered a compelling quarter, surpassing expectations not just on the surface but also in underlying performance. Despite potential impacts from PFA, the MIS Ablation segment's performance does not hinder the company's projection of sustained mid-teens growth. AtriCure continues to focus on enhancing profitability, with anticipation of positive cash flow by FY25.
The firm recognizes AtriCure's Q3 revenues of $116M as marginally surpassing the anticipated figures. The forecasted revenues stood at $113M by the firm and $112M by the consensus. The analyst maintains a positive perspective, noting that AtriCure's current valuation is approximately 2.7 times its FY25 sales, in contrast to its small-cap MedTech peer group, which trades at about 3.7 times.
Here are the latest investment ratings and price targets for $AtriCure (ATRC.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月30日，多家华尔街大行更新了$AtriCure (ATRC.US)$的评级，目标价介于36美元至60美元。
瑞士银行分析师Danielle Antalffy维持买入评级，并将目标价从35美元上调至40美元。
奥本海默控股分析师Suraj Kalia维持买入评级，并将目标价从32美元上调至36美元。
Needham分析师Michael Matson维持买入评级，并将目标价从34美元上调至40美元。
BTIG分析师Marie Thibault维持买入评级，维持目标价53美元。
CCORF分析师William Plovanic维持买入评级，并将目标价从49美元上调至53美元。
此外，综合报道，$AtriCure (ATRC.US)$近期主要分析师观点如下：
atricure交出了一个引人注目的季度，不仅在表面上，也在潜在表现上超出了预期。尽管MIS消融部门可能受到PFA的影响，但公司对持续中等增长的预期并不受阻。atricure继续专注于提升盈利能力，并预计到2025财年实现正现金流。
分析师认可atricure第三季度营收达到11600万美元，略高于预期。公司预测的营收为11300万美元，共识为11200万美元。分析师保持积极态度，指出atricure当前市值约为其2025财年销售额的2.7倍，与其小型医疗科技同行相比，后者的市值约为3.7倍。
以下为今日6位分析师对$AtriCure (ATRC.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
